These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 35755947)
21. Derivation of induced pluripotent stem cells line (RCPCMi007-A-1) with inactivation of the beta-2-microglobulin gene by CRISPR/Cas9 genome editing. Bogomiakova ME; Sekretova EK; Eremeev AV; Shuvalova LD; Bobrovsky PA; Zerkalenkova EA; Lebedeva OS; Lagarkova MA Stem Cell Res; 2021 Aug; 55():102451. PubMed ID: 34237591 [TBL] [Abstract][Full Text] [Related]
22. Repurposing the Cord Blood Bank for Haplobanking of HLA-Homozygous iPSCs and Their Usefulness to Multiple Populations. Lee S; Huh JY; Turner DM; Lee S; Robinson J; Stein JE; Shim SH; Hong CP; Kang MS; Nakagawa M; Kaneko S; Nakanishi M; Rao MS; Kurtz A; Stacey GN; Marsh SGE; Turner ML; Song J Stem Cells; 2018 Oct; 36(10):1552-1566. PubMed ID: 30004605 [TBL] [Abstract][Full Text] [Related]
23. Efficient Gene Editing of Human Induced Pluripotent Stem Cells Using CRISPR/Cas9. Yumlu S; Bashir S; Stumm J; Kühn R Methods Mol Biol; 2019; 1961():137-151. PubMed ID: 30912045 [TBL] [Abstract][Full Text] [Related]
24. CCR5 Disruption in Induced Pluripotent Stem Cells Using CRISPR/Cas9 Provides Selective Resistance of Immune Cells to CCR5-tropic HIV-1 Virus. Kang H; Minder P; Park MA; Mesquitta WT; Torbett BE; Slukvin II Mol Ther Nucleic Acids; 2015 Dec; 4():e268. PubMed ID: 26670276 [TBL] [Abstract][Full Text] [Related]
25. Universal and hypoimmunogenic pluripotent stem cells for clinical usage. Sung TC; Maitiruze K; Pan J; Gong J; Bai Y; Pan X; Higuchi A Prog Mol Biol Transl Sci; 2023; 199():271-296. PubMed ID: 37678974 [TBL] [Abstract][Full Text] [Related]
26. Successful correction of factor V deficiency of patient-derived iPSCs by CRISPR/Cas9-mediated gene editing. Nakamura T; Morishige S; Ozawa H; Kuboyama K; Yamasaki Y; Oya S; Yamaguchi M; Aoyama K; Seki R; Mouri F; Osaki K; Okamura T; Mizuno S; Nagafuji K Haemophilia; 2020 Sep; 26(5):826-833. PubMed ID: 32700411 [TBL] [Abstract][Full Text] [Related]
27. Development of immunocompatible pluripotent stem cells via CRISPR-based human leukocyte antigen engineering. Jang Y; Choi J; Park N; Kang J; Kim M; Kim Y; Ju JH Exp Mol Med; 2019 Jan; 51(1):1-11. PubMed ID: 30617277 [TBL] [Abstract][Full Text] [Related]
28. Antigen Presentation by Individually Transferred HLA Class I Genes in HLA-A, HLA-B, HLA-C Null Human Cell Line Generated Using the Multiplex CRISPR-Cas9 System. Hong CH; Sohn HJ; Lee HJ; Cho HI; Kim TG J Immunother; 2017; 40(6):201-210. PubMed ID: 28604557 [TBL] [Abstract][Full Text] [Related]
29. Generation of two induced pluripotent stem cells lines from a Mucopolysaccharydosis IIIB (MPSIIIB) patient. Vallejo-Diez S; Fleischer A; Martín-Fernández JM; Sánchez-Gilabert A; Bachiller D Stem Cell Res; 2018 Dec; 33():180-184. PubMed ID: 30408744 [TBL] [Abstract][Full Text] [Related]
30. Generation of Mesenchymal Stromal Cells with Low Immunogenicity from Human PBMC-Derived β2 Microglobulin Knockout Induced Pluripotent Stem Cells. Zha S; Tay JC; Zhu S; Li Z; Du Z; Wang S Cell Transplant; 2020; 29():963689720965529. PubMed ID: 33172291 [TBL] [Abstract][Full Text] [Related]
31. Cardiac Regeneration Using Pluripotent Stem Cells and Controlling Immune Responses. Ichimura H; Chino S; Shiba Y Heart Lung Circ; 2023 Jul; 32(7):836-843. PubMed ID: 37029069 [TBL] [Abstract][Full Text] [Related]
32. Generation of universal and hypoimmunogenic human pluripotent stem cells. Ye Q; Sung TC; Yang JM; Ling QD; He Y; Higuchi A Cell Prolif; 2020 Dec; 53(12):e12946. PubMed ID: 33174655 [TBL] [Abstract][Full Text] [Related]
33. Generation of Monoclonal iPSC Lines with Stable Cas9 Expression and High Cas9 Activity. Liao JQ; Zhou G; Zhou Y Methods Mol Biol; 2022; 2454():575-588. PubMed ID: 32567018 [TBL] [Abstract][Full Text] [Related]
34. A clinical-grade HLA haplobank of human induced pluripotent stem cells matching approximately 40% of the Japanese population. Yoshida S; Kato TM; Sato Y; Umekage M; Ichisaka T; Tsukahara M; Takasu N; Yamanaka S Med; 2023 Jan; 4(1):51-66.e10. PubMed ID: 36395757 [TBL] [Abstract][Full Text] [Related]
35. A single allele of the hsa-miR-302/367 cluster maintains human pluripotent stem cells. Sugawara T; Kawamoto Y; Kawasaki T; Umezawa A; Akutsu H Regen Ther; 2022 Dec; 21():37-45. PubMed ID: 35702483 [TBL] [Abstract][Full Text] [Related]
36. Human Leukocyte Antigen Class I Pseudo-Homozygous Mesenchymal Stem Cells Derived from Human Induced Pluripotent Stem Cells. Kwon D; Ahn HJ; Han MJ; Ji M; Ahn J; Seo KW; Kang KS Stem Cell Rev Rep; 2020 Aug; 16(4):792-808. PubMed ID: 32712868 [TBL] [Abstract][Full Text] [Related]
37. Human Leukocyte Antigen Class I and II Knockout Human Induced Pluripotent Stem Cell-Derived Cells: Universal Donor for Cell Therapy. Mattapally S; Pawlik KM; Fast VG; Zumaquero E; Lund FE; Randall TD; Townes TM; Zhang J J Am Heart Assoc; 2018 Dec; 7(23):e010239. PubMed ID: 30488760 [TBL] [Abstract][Full Text] [Related]
38. Generation of B2M bi-allelic knockout human induced pluripotent stem cells (MUSIi001-A-1) using a CRISPR/Cas9 system. Thongsin N; Wattanapanitch M Stem Cell Res; 2021 Oct; 56():102551. PubMed ID: 34628247 [TBL] [Abstract][Full Text] [Related]